Fidelity Investments’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.2K | Buy |
16,509
+917
| +6% | +$1.11K | ﹤0.01% | 4625 |
|
|
2025
Q4 | $20K | Sell |
15,592
-2,770
| -15% | -$3.72K | ﹤0.01% | 4467 |
|
|
2025
Q3 | $23.9K | Buy |
18,362
+256
| +1% | +$335 | ﹤0.01% | 4286 |
|
|
2025
Q2 | $21.7K | Buy |
18,106
+5,688
| +46% | +$6.3K | ﹤0.01% | 4254 |
|
|
2025
Q1 | $13.4K | Buy |
12,418
+2,936
| +31% | +$4.12K | ﹤0.01% | 4383 |
|
|
2024
Q4 | $16.6K | Buy |
9,482
+1,201
| +15% | +$2.24K | ﹤0.01% | 4261 |
|
|
2024
Q3 | $16K | Buy |
8,281
+4,377
| +112% | +$8.57K | ﹤0.01% | 4275 |
|
|
2024
Q2 | $6.91K | Sell |
3,904
-2,413
| -38% | -$5.9K | ﹤0.01% | 4453 |
|
|
2024
Q1 | $17.1K | Buy |
6,317
+6,266
| +12,286% | +$15.1K | ﹤0.01% | 4075 |
|
|
2023
Q4 | $113 | Hold |
51
| – | – | ﹤0.01% | 4931 |
|
|
2023
Q3 | $148 | Hold |
51
| – | – | ﹤0.01% | 4815 |
|
|
2023
Q2 | $98 | Sell |
51
-586
| -92% | -$1.16K | ﹤0.01% | 4961 |
|
|
2023
Q1 | $1.24K | Sell |
637
-5,878
| -90% | -$11.6K | ﹤0.01% | 4713 |
|
|
2022
Q4 | $7.62K | Buy |
+6,515
| New | +$8.02K | ﹤0.01% | 4109 |
|
|
2022
Q3 | – | Sell |
-4,321
| Closed | -$7K | – | 5188 |
|
|
2022
Q2 | $7K | Buy |
4,321
+718
| +20% | +$1.78K | ﹤0.01% | 4221 |
|
|
2022
Q1 | $13K | Buy |
+3,603
| New | +$12.4K | ﹤0.01% | 4158 |
|
|
2021
Q4 | – | Sell |
-5
| Closed | – | – | 4692 |
|
|
2021
Q3 | $0 | Buy |
+5
| New | +$33 | ﹤0.01% | 4727 |
|
|
2021
Q2 | – | Sell |
-10
| Closed | – | – | 4599 |
|
|
2021
Q1 | $0 | Sell |
10
-2,944,190
| -100% | -$16.2M | ﹤0.01% | 4296 |
|
|
2020
Q4 | $17.7M | Sell |
2,944,200
-63,910
| -2% | -$420K | ﹤0.01% | 1767 |
|
|
2020
Q3 | $22.4M | Buy |
+3,008,110
| New | +$20.8M | ﹤0.01% | 1512 |
|
|
2019
Q3 | – | Sell |
-1,820,000
| Closed | -$22.4M | – | 4040 |
|
|
2019
Q2 | $22.4M | Hold |
1,820,000
| – | – | ﹤0.01% | 1578 |
|
|
2019
Q1 | $24.2M | Buy |
+1,820,000
| New | +$19.2M | ﹤0.01% | 1518 |
|
|
2017
Q1 | – | Sell |
-160,000
| Closed | -$1.17M | – | 2684 |
|
|
2016
Q4 | $1.17M | Buy |
+160,000
| New | +$1M | ﹤0.01% | 2452 |
|
|
2015
Q4 | – | Sell |
-312,345
| Closed | -$2.53M | – | 2753 |
|
|
2015
Q3 | $2.53M | Sell |
312,345
-780,800
| -71% | -$12.3M | ﹤0.01% | 2357 |
|
|
2015
Q2 | $26.5M | Sell |
1,093,145
-60,300
| -5% | -$1.9M | ﹤0.01% | 1619 |
|
|
2015
Q1 | $48.6M | Sell |
1,153,445
-80,200
| -7% | -$3.17M | 0.01% | 1345 |
|
|
2014
Q4 | $41.6M | Buy |
1,233,645
+206,402
| +20% | +$5.85M | 0.01% | 1420 |
|
|
2014
Q3 | $25.2M | Sell |
1,027,243
-99,302
| -9% | -$2.79M | ﹤0.01% | 1646 |
|
|
2014
Q2 | $33.1M | Sell |
1,126,545
-225,342
| -17% | -$7.22M | ﹤0.01% | 1552 |
|
|
2014
Q1 | $59.6M | Sell |
1,351,887
-400,452
| -23% | -$17.6M | 0.01% | 1241 |
|
|
2013
Q4 | $67.2M | Buy |
1,752,339
+300,000
| +21% | +$8.84M | 0.01% | 1167 |
|
|
2013
Q3 | $31.9M | Sell |
1,452,339
-275,600
| -16% | -$5.41M | ﹤0.01% | 1493 |
|
|
2013
Q2 | $30.2M | Buy |
+1,727,939
| New | +$30.3M | ﹤0.01% | 1481 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Fidelity Investments's LAB Position: Q1 2026 in Review
Fidelity Investments increased its Standard BioTools (LAB) stake by 5.9% in Q1 2026, buying an estimated $1.11K and bringing the position to 16,509 shares worth $15.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4625.
Fidelity Investments first reported a position in LAB in Q2 2013 and has held it in 33 quarters since. The position peaked at $67.2M in Q4 2013. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Fidelity Investments held 16,509 shares of Standard BioTools worth $15.2K as of Q1 2026.
- Fidelity Investments bought 917 Standard BioTools shares in Q1 2026, an estimated $1.11K.
- Standard BioTools made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4625 holding.
- Fidelity Investments first reported a position in Standard BioTools in Q2 2013 and has held it in 33 quarters since.
- Fidelity Investments's Standard BioTools position peaked at $67.2M in Q4 2013.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.